Tag: DECLARE TIMI-58

DECLARE TIMI-58 trial shows benefits of dapagliflozin in high-risk subgroups

Conference
ACC 2019
Type
Peer-reviewed article

4 June 2019 14:16
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com